"The Power 15 Study: Safety Study of Inhalation of Ventavis With the Power Disc-15 Setting"

PHASE2TerminatedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

November 30, 2010

Study Completion Date

June 30, 2011

Conditions
Pulmonary Hypertension
Interventions
DRUG

Iloprost PD-6

Period I: Patients received iloprost administered using PD-6 for the 37 days prior to the first dosing of iloprost using PD-15. Iloprost inhalation solution was delivered using the I-neb® AAD System. Patients were required to use their own I-neb®.

DRUG

Iloprost PD-15

Period II: Iloprost inhalation solution was delivered using the investigational product PD-15 with I-neb® AAD System for 37 days. Patients were required to use their own I-neb®.

Trial Locations (12)

10032

Columbia University Medical Center, New York

New York Presbyterian Hospital, New York

15213

University of Pittsburgh Medical Center, Pittsburgh

21201

University of Maryland Hospital, Baltimore

27710

Duke University Medical Center, Durham

52242

University of Iowa Hospital and Clinics, Iowa City

53215

Aurora Medical Group - Cardiovascular Services, Milwaukee

70112

Ochsner Clinic Foundation, New Orleans

77030

Baylor College of Medicine, Houston

78229

Diagnostic Research Group, San Antonio

85006

Pulmonary Associates, Phoenix

92037

UCSD Medical Center, Thorton Hospital, La Jolla

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Actelion

INDUSTRY

NCT00467896 - "The Power 15 Study: Safety Study of Inhalation of Ventavis With the Power Disc-15 Setting" | Biotech Hunter | Biotech Hunter